<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vemurafenib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vemurafenib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vemurafenib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="16799" href="/d/html/16799.html" rel="external">see "Vemurafenib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13187339"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zelboraf</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871375"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zelboraf</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13182295"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, BRAF Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F13202882"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Do not initiate vemurafenib in patients with electrolyte abnormalities that are not correctable, long QT syndrome, or taking concomitant medication known to prolong the QT interval. Do not initiate if baseline QTc &gt;500 msec.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3dc1ec4-fc97-45fc-b6c0-59f86438b4c9">Erdheim-Chester disease, with BRAF V600 mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erdheim-Chester disease, with BRAF V600 mutation:</b>
<b>Oral:</b> 960 mg every 12 hours; continue until disease progression or unacceptable toxicity (Diamond 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebfa0bf3-ebf9-4936-aa86-5857c17abf26">Hairy cell leukemia, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hairy cell leukemia, relapsed or refractory (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with rituximab: </i>
<b>Oral: </b>Induction: 960 mg twice daily for 4 weeks (in combination with rituximab), followed by 2 weeks of rest, followed by a second induction cycle consisting of vemurafenib 960 mg twice daily for 4 weeks (in combination with rituximab). After the second induction cycle, 4 additional rituximab doses were administered as consolidation therapy, for a total of 8 rituximab doses (Tiacci 2021). Refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>As a single agent:</i>
<b>Oral:</b> 960 mg twice daily for a minimum of 8 to 12 weeks; patients with residual disease could continue vemurafenib for up to 8 to 12 additional weeks (Handa 2022; Tiacci 2015). Refer to protocols for further information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="431644c1-9d83-42e1-9012-d99d4139089e">Langerhans cell histiocytosis, BRAF V600-mutated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Langerhans cell histiocytosis, BRAF V600-mutated (off-label use): Oral: </b>960 mg twice daily until disease progression or unacceptable toxicity (Diamond 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b8b61a8-a96f-4706-a076-2ede2ffc94b3">Melanoma, unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>With BRAF V600E mutation: Oral:</b> 960 mg every 12 hours; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>With BRAF V600K mutation (off-label use): Oral:</b> 960 mg every 12 hours; continue until disease progression or unacceptable toxicity (Chapman 2011; Sosman 2012). Refer to protocol for dosage modification details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>With BRAF V600 mutations (off-label combinations):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with cobimetinib: </i>
<b>Oral: </b>960 mg every 12 hours; continue until disease progression or unacceptable toxicity (Larkin 2014). Refer to protocol for dosage modification details.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with cobimetinib and atezolizumab</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Cycle 1 (with cobimetinib only): <b>Oral: </b>960 mg every 12 hours on days 1 to 21 of a 28-day cycle, followed by 720 mg every 12 hours on days 22 to 28 of cycle 1 (Gutzmer 2020).</p>
<p style="text-indent:-2em;margin-left:8em;">Cycle 2 and beyond (with cobimetinib and atezolizumab): <b>Oral: </b>720 mg every 12 hours until disease progression or unacceptable toxicity (Gutzmer 2020). Refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>With BRAF mutation and brain metastases (off-label combination): Note: </b>Vemurafenib in combination with cobimetinib has been used for the treatment of BRAF mutant melanoma with brain metastases, although data are limited (Drago 2019).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52bc184c-eb96-403f-9572-78c866d70315">Non–small cell lung cancer, relapsed/refractory, with BRAF V600 mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, relapsed/refractory, with BRAF V600 mutation (off-label use): Oral:</b> 960 mg twice daily until disease progression or unacceptable toxicity (Hyman 2015; Mazieres 2020). Refer to protocol for dosage modification details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8a925853-2fb4-49f6-a42e-e1c59aa8f471">Thyroid cancer, papillary, recurrent or metastatic, BRAF V600E-mutated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, papillary, recurrent or metastatic, BRAF V600E-mutated (off-label use): Oral: </b>960 mg twice daily until disease progression or unacceptable toxicity (Brose 2016).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed doses:</b> A missed dose may be administered up to 4 hours prior to the next scheduled dose. If it is within 4 hours of the next scheduled dose, administer the next dose at the regular schedule. If vomiting occurs after a dose is taken, do not take an additional dose; continue with the next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult Drug Interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991545"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney impairment prior to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, no need for dose adjustment is expected (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis, intermittent (thrice weekly): No need for dose adjustment is expected (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney toxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Nephrotoxicity/creatinine abnormalities: Refer to dosage adjustment for toxicity and manage with dose reduction, treatment interruption, or discontinuation.</p></div>
<div class="block doha drugH1Div" id="F50988680"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (total bilirubin 1 to 3 times ULN): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (total bilirubin &gt;3 times ULN): There are no dosage adjustments provided in manufacturer's labeling; however, no need for dose adjustment is expected (monitor LFTs twice a week as clinically indicated) (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Hepatotoxicity/lab abnormalities: Refer to dosage adjustment for toxicity and manage with dose reduction, treatment interruption, or discontinuation.</p></div>
<div class="block dot drugH1Div" id="F13202884"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not dose reduce below 480 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Grade 1 or grade 2 (tolerable) toxicity:</b> No dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Grade 2 (intolerable) or grade 3 toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">First incident: Interrupt treatment until toxicity returns to grade 0 or 1, then resume at 720 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Second incident: Interrupt treatment until toxicity returns to grade 0 or 1, then resume at 480 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Third incident: Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Grade 4 toxicity: </b></p>
<p style="text-indent:-2em;margin-left:4em;">First incident: Interrupt treatment until toxicity returns to grade 0 or 1, then resume at 480 mg twice daily <b>or</b> discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:4em;">Second incident: Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Specific toxicities:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dermatologic toxicity, severe: </i>Permanently discontinue vemurafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dupuytren contracture and plantar fascial fibromatoses:</i> May require therapy interruption, dosage reduction, or treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hypersensitivity, severe: </i>Permanently discontinue vemurafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>New primary cutaneous malignancies: </i>No dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Photosensitivity: </i>Dosage modifications are recommended for intolerable ≥ grade 2 photosensitivity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>QTc interval changes:</i></p>
<p style="text-indent:-2em;margin-left:6em;">QTc &gt;500 msec (grade ≥3): Temporarily withhold treatment, correct electrolytes and control risk factors for QT prolongation; may reinitiate with a dose reduction once QTc ≤500 msec (≤ grade 2).</p>
<p style="text-indent:-2em;margin-left:6em;">QTc persistently &gt;500 msec and &gt;60 msec above baseline: Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uveitis: </i>May be managed with corticosteroid and mydriatic eye drops.</p></div>
<div class="block doe drugH1Div" id="F13202883"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F13202866"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (≤55%), hypertension (≤36%), peripheral edema (17% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (38% to ≤55%), peripheral sensory neuropathy (≤36%), headache (23% to 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Maculopapular rash (9% to ≤59%), alopecia (36% to ≤55%), skin rash (37% to 52%), hyperkeratosis (24% to ≤50%; seborrheic: 10% to ≤41%; pilaris: ≤32%; actinic: 8% to ≤32%), skin photosensitivity (33% to 49%), xeroderma (16% to ≤45%), palmar-plantar erythrodysesthesia (≤41%), pruritus (23% to ≤36%), nevus (≤23%), sunburn (10% to ≤23%), papular rash (5% to ≤23%), erythema (8% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (28% to ≤50%), nausea (≤32% to 37%), vomiting (18% to 26%), decreased appetite (18% to 21%), constipation (12% to 16%), dysgeusia (11% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Cutaneous papilloma (21% to ≤55%), keratoacanthoma (≤41%), squamous cell carcinoma of skin (≤41%; grade 3: 22% to ≤36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (5% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (53% to ≤82%), myalgia (13% to 24%), limb pain (9% to 18%), back pain (8% to 11%), musculoskeletal pain (8% to 11%), weakness (2% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (up to 3x ULN: 26% to 86%; greater than 3x ULN: 1% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (8% to ≤36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fibrosis (Dupuytren contracture) (&lt;20%), fever (17% to 19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, hypotension, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Cranial nerve palsy (facial), dizziness, peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema nodosum, folliculitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Basal cell carcinoma, malignant melanoma (new primary), squamous cell carcinoma (oropharyngeal)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT (≥ grade 3: 3% to ≤9%), increased serum alkaline phosphatase (≥ grade 3: 3% to ≤5%), increased serum bilirubin (≥ grade 3: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, panniculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, iritis, photophobia, uveitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Secondary acute myelocytic leukemia</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute interstitial nephritis, acute tubular necrosis, chronic myelomonocytic leukemia with NRAS mutation (progression of preexisting condition), DRESS syndrome, hepatic injury, increased serum AST, local acneiform eruptions (Ansai 2016), neutropenia, pancreatitis, plantar fasciitis, recall skin sensitization, retinal vein occlusion</p></div>
<div class="block coi drugH1Div" id="F13202863"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to vemurafenib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F13202864"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Dermatologic reactions have been observed, including case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fibroproliferative disease: Cases of Dupuytren contracture and plantar fascial fibromatosis have been reported with vemurafenib use (Chan 2015; Perez 2017; Vandersleyen 2016). In June of 2017, the vemurafenib manufacturer issued a “Dear Healthcare Provider” letter stating that the majority of cases reported were mild to moderate, although disabling Dupuytren contracture cases have been observed. The median time to onset was 224 days from therapy initiation; the majority of patients experienced symptom resolution or improvement with interruption or discontinuation of vemurafenib (Perez 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Liver injury has been reported and may cause functional impairment such as coagulopathy or other organ dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylaxis and severe hypersensitivity may occur during treatment or upon reinitiation. Serious reactions have included generalized rash, erythema, hypotension, and drug rash with eosinophilia and systemic symptoms (DRESS syndrome).</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancies: Cutaneous squamous cell carcinomas (cuSCC), keratoacanthomas, and melanoma have been reported (at a higher rate in patients receiving vemurafenib compared to control). Cutaneous SCC generally occurs early in the treatment course (median onset: 7 to 8 weeks in melanoma patients and ~12 weeks in Erdheim Chester disease [ECD] patients) and is managed with excision (while continuing vemurafenib treatment). Approximately one-third of melanoma patients experienced &gt;1 cuSCC occurrence and the median time between occurrences was 6 weeks. Potential risk factors for cuSCC include age ≥65 years, history of skin cancer, or chronic sun exposure. In patients receiving vemurafenib for the treatment of melanoma, new primary malignant melanomas have been reported (rare). Noncutaneous squamous cell carcinomas (non-cuSCC) of the head and neck have also been observed; monitor closely for signs/symptoms. Vemurafenib may promote malignancies correlated with RAS activation; monitor for signs/symptoms of other malignancies. Myeloid malignancies in patients with ECD have been reported, including patients receiving vemurafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Acute kidney injury, including interstitial nephritis, acute tubular necrosis, and serum creatinine elevations (grades 1 to 4) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Uveitis (including iritis), blurred vision, and photophobia may occur. Retinal vein occlusion has been reported in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Pancreatitis has been reported (rare). Onset occurs within 2 weeks after initiation, with exacerbation occurring upon rechallenge at a reduced dose (Muluneh 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Photosensitivity ranging from mild to severe has been reported. Advise patients to avoid sun exposure and wear protective clothing and use effective UVA/UVB sunscreen and lip balm (SPF ≥30) when outdoors.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: QT prolongation (dose-dependent) has been observed; may lead to increased risk for ventricular arrhythmia, including torsades de pointes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation sensitization/recall: Radiation sensitization and recall (some cases may be severe or involve cutaneous and visceral organs) have been reported in patients treated with radiation prior to, during, or after treatment with vemurafenib; fatal cases have been reported in patients with visceral organ involvement.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age may be at increased risk for development of cuSCC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• BRAF genomics: Only patients with a BRAF V600 mutation-positive melanoma (including BRAF V600E) will benefit from treatment; mutation must be detected and confirmed by an approved test prior to treatment. The cobas 4800 BRAF V600 Mutation Test was used in clinical trials and is approved to detect BRAF V600E mutation.</p></div>
<div class="block foc drugH1Div" id="F13187340"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zelboraf: 240 mg</p></div>
<div class="block geq drugH1Div" id="F13202858"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322912"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zelboraf Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $61.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871376"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zelboraf: 240 mg</p></div>
<div class="block accres drugH1Div" id="F13207302"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Available through specialty pharmacies. Further information may be obtained from the manufacturer, Genentech, at 1-888-249-4918, or at http://www.zelboraf.com.</p></div>
<div class="block adm drugH1Div" id="F13202887"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Doses should be administered orally in the morning and evening, ~12 hours apart. May administer with or without a meal. If vomiting occurs after a dose is taken, do not take an additional dose; continue with the next scheduled dose.</p>
<p style="text-indent:0em;margin-top:2em;">Swallow whole with a glass of water; do not crush or chew. There are case reports of vemurafenib administration after crushing (Janson 2013; Khimani 2014), however vemurafenib is nearly insoluble in water and is manufactured as a microprecipitated bulk powder core (to improve solubility/bioavailability) within a film coated tablet (Shah 2013). Pharmacokinetics and efficacy of administration other than swallowing tablets whole have not been determined.</p></div>
<div class="block hazard drugH1Div" id="F49104602"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block meg drugH1Div" id="F13207300"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F202429s016lbl.pdf%23page%3D21&amp;token=P1HZGwNROzSygfF%2BYME8Xd274Q1Gq98vqowhvT7hJ5E2J9aXlA9OAKVqSjzjQOtTTjsD%2FdV3jAWmNbao7R3FyEthlPsIakStTW4QuI%2FT6dx7QLoFOKGVHFO6bjLartMf&amp;TOPIC_ID=16798" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf#page=21</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F13182297"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic, with BRAF 600E mutation:</b> Treatment of unresectable or metastatic melanoma in patients with a BRAF V600E mutation (as detected by an approved test)</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not indicated for treatment of wild-type BRAF melanoma</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Erdheim-Chester disease, with BRAF V600 mutation: </b>Treatment of Erdheim-Chester disease (ECD) in patients with a BRAF V600 mutation</p></div>
<div class="block off-label drugH1Div" id="F25590298"><span class="drugH1">Use: Off-Label: Adult</span><p>Hairy cell leukemia, relapsed or refractory; Langerhans cell histiocytosis, with BRAF V600 mutation; Melanoma, metastatic, with BRAF V600K mutation; Non-small cell lung cancer, relapsed/refractory, with BRAF V600 mutation; Thyroid cancer, papillary, recurrent or metastatic, BRAF V600E-mutated</p></div>
<div class="block mst drugH1Div" id="F13182294"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vemurafenib may be confused with axitinib, cabozantinib, cobimetinib, dabrafenib, encorafenib, ponatinib, regorafenib, SORAfenib, trametinib, vandetanib, venetoclax, vismodegib</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300213"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (moderate), CYP2D6 (weak), P-glycoprotein/ABCB1; <b>Induces</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F13225913"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agomelatine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Agomelatine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron.  Management: Avoid concomitant use of alosetron and moderate CYP1A2 inhibitors whenever possible. If combined use is necessary, monitor for increased alosetron effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: CYP1A2 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Anagrelide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bendamustine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bendamustine.  Management: Consider alternatives to moderate CYP1A2 inhibitors during therapy with bendamustine due to the potential for increased bendamustine plasma concentrations and increased bendamustine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromazepam: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bromazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Vemurafenib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Vemurafenib. Management: Avoid coadministration of vemurafenib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase the vemurafenib dose by 240 mg as tolerated. Resume prior vemurafenib dose 2 weeks after discontinuation of strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Vemurafenib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vemurafenib. Management: Avoid concurrent use of vemurafenib with strong CYP3A4 inhibitors when possible. If concomitant use is unavoidable, consider a vemurafenib dose reduction if clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of Vemurafenib. Dabrafenib may decrease the serum concentration of Vemurafenib. Management: Monitor for decreased vemurafenib efficacy, QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Vemurafenib may increase the serum concentration of Digoxin.  Management: Avoid coadministration of vemurafenib and digoxin when possible. If combined, measure digoxin levels and reduce digoxin concentrations by either reducing the digoxin dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of Vemurafenib. Encorafenib may decrease the serum concentration of Vemurafenib. Management: Avoid use of vemurafenib and encorafenib if possible. If combined increase the vemurafenib dose by 240 mg as tolerated. Resume prior vemurafenib dose 2 weeks after encorafenib discontinuation. Monitor for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Fexinidazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Weak) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipilimumab: May enhance the hepatotoxic effect of Vemurafenib. Management: Consider alternatives to this combination when possible.  Use of this combination should only be undertaken with extra close monitoring of liver function (hepatic transaminases and bilirubin) and signs/symptoms of hepatotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Vemurafenib may enhance the QTc-prolonging effect of PAZOPanib. Vemurafenib may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: Avoid concomitant use of pirfenidone and moderate CYP1A2 inhibitors whenever possible. If combined, decrease the pirfenidone dose to 1,602 mg per day (534 mg three times daily) and monitor for increased pirfenidone toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Vemurafenib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of other QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Kinase Inhibitors (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Vemurafenib. QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Vemurafenib. Management: Avoid concomitant use of vemurafenib and strong CYP3A4 inhibitors that prolong the QTc interval whenever possible. If combined monitor patients for vemurafenib toxicities including QTc prolongation and TdP, and consider a vemurafenib dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): Vemurafenib may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Vemurafenib.  Management: Avoid concomitant use of vemurafenib and strong CYP3A4 inhibitors that prolong the QTc interval whenever possible. If combined monitor patients for vemurafenib toxicities including QTc prolongation and TdP, and consider a vemurafenib dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline.  Management: Limit rasagiline dose to 0.5 mg once daily in patients taking moderate CYP1A2 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: May enhance the QTc-prolonging effect of Vemurafenib. Vemurafenib may increase the serum concentration of RisperiDONE. Management: Monitor for increased risperidone toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPivacaine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Theophylline Derivatives.  Management: Consider avoidance of this combination. If coadministration is necessary, monitor for increased theophylline serum concentrations and toxicities when combined. Theophylline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of TiZANidine.  Management: If combined use cannot be avoided, initiate tizanidine in adults at 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with P-glycoprotein (P-gp) inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Vemurafenib may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F45746240"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit and grapefruit juice may inhibit CYP3A4-mediated metabolism of vemurafenib. Management: Monitor for increased effects/toxicity with concomitant use.</p></div>
<div class="block rep_considerations drugH1Div" id="F53632821"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should use effective contraception during treatment and for at least 2 weeks after the last vemurafenib dose.</p></div>
<div class="block pri drugH1Div" id="F13202860"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Vemurafenib crosses the placenta and can be detected in the newborn at delivery (Maleka 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action, vemurafenib may cause fetal harm if administered during pregnancy. Outcome data following maternal use of vemurafenib during pregnancy are available from case reports following treatment for melanoma (de Haan 2018; Maleka 2013; Marcé 2019; Pagan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach (ESMO [Peccatori 2013]). Treatment of melanoma in pregnant patients should consider the trimester of pregnancy and the stage of disease at diagnosis (Swetter 2019).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F13202862"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if vemurafenib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 2 weeks after the last vemurafenib dose.</p></div>
<div class="block mop drugH1Div" id="F13202900"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Confirm BRAF V600 mutation status (in patients with melanoma). Monitor liver transaminases, alkaline phosphatase, and bilirubin at baseline and monthly during treatment (or as clinically appropriate). In patients with severe hepatic impairment, monitor LFTs twice a week as clinically indicated (Krens 2019). Monitor serum creatinine at baseline and periodically during treatment. Monitor CBC in patients with Erdheim-Chester disease and coexisting myeloid malignancies. Electrolytes (calcium, magnesium, and potassium) at baseline and after dosage modification. ECG at baseline, 15 days after initiation, then monthly for 3 months, then every 3 months thereafter (more frequently if clinically appropriate) and with dosage adjustments. Consider evaluating unexplained abdominal pain for pancreatitis (eg, serum lipase and amylase; abdominal CT) as clinically indicated. Dermatology evaluation (for new skin lesions) at baseline and every 2 months during treatment; also consider continued monitoring for 6 months after completion of treatment. Monitor for signs/symptoms of hypersensitivity reactions, uveitis, and malignancies; monitor for signs of radiation sensitization and recall. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring specifics: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Assess BP at baseline and each clinical visit (as well as outpatient monitoring weekly for initial 3 months, then monthly thereafter). In patients receiving cobimetinib plus vemurafenib assess ECG at baseline, at 2 and 4 weeks, then every 3 months thereafter; obtain a baseline echocardiography in high- and very-high risk patients scheduled to receive BRAF-MEK inhibitor combination therapy (consider repeating every 4 months during the first year); consider echocardiography in low- and moderate-risk patients scheduled to receive BRAF-MEK inhibitor combination therapy (ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F13202872"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vemurafenib is a low molecular weight oral BRAF kinase inhibitor (potent) which inhibits tumor growth in melanomas by inhibiting kinase activity of certain mutated forms of BRAF, including BRAF with V600E mutation, thereby blocking cellular proliferation in melanoma cells with the mutation. It does not have activity against cells with wild-type BRAF. BRAF V600E activating mutations are present in ~50% of melanomas; V600E mutation involves the substitution of glutamic acid for valine at amino acid 600.</p></div>
<div class="block phk drugH1Div" id="F13202874"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~106 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%, to albumin and α<sub>1</sub>-acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Mean: 64% at steady state.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: 57 hours (range: 30 to 120 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~94%); urine (~1%).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 31 L/day.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13733209"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Zelboraf</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22431777">
<a name="22431777"></a>Alloo A, Garibyan L, LeBoeuf N, et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. <i>Arch Dermatol</i>. 2012;148(3):363-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/22431777/pubmed" id="22431777" target="_blank">22431777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27511106">
<a name="27511106"></a>Ansai O, Fujikawa H, Shimomura Y, Abe R. Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib [published online August 11, 2016]. <i>J Dermatol</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/27511106/pubmed" id="27511106" target="_blank">27511106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bloom KJ, Anderson SM, Schilling RC, et al, “Molecular Testing for BRAF V600 Mutations in the BRIM-2 Trial of the BRAF Inhibitor Vemurafenib in Metastatic Melanoma,” <i>J Clin Oncol</i>, 2011, 29(15s):10523 [abstract 10523 from ASCO 2011 Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20823850">
<a name="20823850"></a>Bollag G, Hirth P, Tsai J, et al, “Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma,” <i>Nature</i>, 2010, 467(7315):596-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/20823850/pubmed" id="20823850" target="_blank">20823850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27460442">
<a name="27460442"></a>Brose MS, Cabanillas ME, Cohen EE, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. <i>Lancet Oncol</i>. 2016;17(9):1272-1282. doi:10.1016/S1470-2045(16)30166-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/27460442/pubmed" id="27460442" target="_blank">27460442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23134356">
<a name="23134356"></a>Callahan MK, Rampal R, Harding JJ, et al, “Progression of RAS-Mutant Leukemia During RAF Inhibitor Treatment,” <i>N Engl J Med,</i> 2012, 367(24):2316-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/23134356/pubmed" id="23134356" target="_blank">23134356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26152183">
<a name="26152183"></a>Chan SW, Vorobiof DA. Dupuytren's contractures associated with the BRAF inhibitor vemurafenib: a case report. <i>J Med Case Rep.</i> 2015;9:158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/26152183/pubmed" id="26152183" target="_blank">26152183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21639808">
<a name="21639808"></a>Chapman PB, Hauschild A, Robert C, et al, “Improved Survival With Vemurafenib in Melanoma With BRAF V600E Mutation,” <i>N Engl J Med</i>, 2011, 364(26):2507-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/21639808/pubmed" id="21639808" target="_blank">21639808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29606950">
<a name="29606950"></a>de Haan J, van Thienen JV, Casaer M, et al. Severe adverse reaction to vemurafenib in a pregnant woman with metastatic melanoma. <i>Case Rep Oncol</i>. 2018;11(1):119-124. doi:10.1159/000487128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/29606950/pubmed" id="29606950" target="_blank">29606950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29188284">
<a name="29188284"></a>Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. <i>JAMA Oncol</i>. 2018;4(3):384-388. doi:10.1001/jamaoncol.2017.5029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/29188284/pubmed" id="29188284" target="_blank">29188284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30376465">
<a name="30376465"></a>Drago JZ, Lawrence D, Livingstone E, et al. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. <i>Melanoma Res</i>. 2019;29(1):65-69. doi:10.1097/CMR.0000000000000527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/30376465/pubmed" id="30376465" target="_blank">30376465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818844">
<a name="20818844"></a>Flaherty KT, Puzanov I, Kim KB, et al, “Inhibition of Mutated, Activated BRAF in Metastatic Melanoma,” <i>N Engl J Med</i>, 2010, 363(9):809-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/20818844/pubmed" id="20818844" target="_blank">20818844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32534646">
<a name="32534646"></a>Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i>. 2020;395(10240):1835-1844. doi:10.1016/S0140-6736(20)30934-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/32534646/pubmed" id="32534646" target="_blank">32534646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35930750">
<a name="35930750"></a>Handa S, Lee JO, Derkach A, et al. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. <i>Blood</i>. 2022;140(25):2663-2671. doi:10.1182/blood.2022016183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/35930750/pubmed" id="35930750" target="_blank">35930750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25422482">
<a name="25422482"></a>Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. <i>J Clin Oncol</i>. 2015 ;33(5):411-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/25422482/pubmed" id="25422482" target="_blank">25422482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32985015">
<a name="32985015"></a>Hazim AZ, Ruan GJ, Ravindran A, et al. Efficacy of BRAF-inhibitor therapy in BRAF<sup>V600E</sup>-mutated adult Langerhans cell histiocytosis. <i>Oncologist</i>. 2020;25(12):1001-1004. doi:10.1002/onco.13541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/32985015/pubmed" id="32985015" target="_blank">32985015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26287849">
<a name="26287849"></a>Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. <i>N Engl J Med</i>. 2015;373(8):726-736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/26287849/pubmed" id="26287849" target="_blank">26287849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Janson B, Whitney K, Wieringa S, et al. Vemurafenib – can it be crushed or chewed? <i>Asia Pacific J Clin Oncol</i>. 2013;0(suppl 3):146 [Abstract 299 from Clinical Oncological Society of Australia].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24490602">
<a name="24490602"></a>Khimani F, Hoban C, Williams V, et al. Efficacy of solubilized vemurafenib administered via nasogastric tube. <i>Future Oncol</i>. 2014;10(2):165-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/24490602/pubmed" id="24490602" target="_blank">24490602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25265494">
<a name="25265494"></a>Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>N Engl J Med</i>. 2014;371(20):1867-1876.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/25265494/pubmed" id="25265494" target="_blank">25265494</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Larkin JM, Yan Y, McArthur GA, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. <i>J Clin Oncol</i>. 2015; 33(15s):9006 [Abstract 9006 from ASCO 2015 annual meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23401457">
<a name="23401457"></a>Maleka A, Enblad G, Sjörs G, Lindqvist A, Ullenhag GJ. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. <i>J Clin Oncol</i>. 2013;31(11):e192-e193. doi:10.1200/JCO.2012.45.2870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/23401457/pubmed" id="23401457" target="_blank">23401457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31246727">
<a name="31246727"></a>Marcé D, Cornillier H, Denis C, Jonville-Bera AP, Machet L. Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicity. <i>Melanoma Res</i>. 2019;29(4):446-447. doi:10.1097/CMR.0000000000000600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/31246727/pubmed" id="31246727" target="_blank">31246727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31959346">
<a name="31959346"></a>Mazieres J, Cropet C, Montané L, et al. Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutations. <i>Ann Oncol</i>. 2020;31(2):289-294. doi:10.1016/j.annonc.2019.10.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/31959346/pubmed" id="31959346" target="_blank">31959346</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  McArthur GA, Ribas A, Chapman PB, et al, “Molecular Analyses From a Phase I Trial of Vemurafenib to Study Mechanism of Action (MOA) and Resistance in Repeated Biopsies From BRAF Mutation–Positive Metastatic Melanoma Patients (pts),” <i>J Clin Oncol</i>, 2011, 29(15s):8502 [abstract 8502 from ASCO 2011 Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23436544">
<a name="23436544"></a>Muluneh B, Buie LW, and Collichio F. Vemurafenib-associated pancreatitis: case report. <i>Pharmacotherapy</i>. 2013;33(4):e43-e44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/23436544/pubmed" id="23436544" target="_blank">23436544</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Available at <a href="http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40_conversion" target="_blank">http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40_conversion</a>. Last accessed October 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36534938">
<a name="36534938"></a>Owen DH, Singh N, Ismaila N, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO living guideline, version 2022.2. <i>J Clin Oncol</i>. 2023;41(5):e10-e20. doi:10.1200/JCO.22.02124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/36534938/pubmed" id="36534938" target="_blank">36534938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31700806">
<a name="31700806"></a>Pagan M, Jinks H, Sewell M. Treatment of metastatic malignant melanoma during pregnancy with a BRAF kinase inhibitor. <i>Case Rep Womens Health</i>. 2019;24:e00142. doi:10.1016/j.crwh.2019.e00142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/31700806/pubmed" id="31700806" target="_blank">31700806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Perez EA. Dear healthcare provider letter: Risk of Dupuytren's contracture and plantar fascial fibromatosis with Zelboraf (vemurafenib). South San Francisco, CA: Genentech USA, Inc; June 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23550685">
<a name="23550685"></a>Ribas A, Hodi FS, Callahan M, et al, “Hepatotoxicity With Combination of Vemurafenib and Ipilimumab," <i>N Engl J Med</i>, 2013, 368(14):1365-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/23550685/pubmed" id="23550685" target="_blank">23550685</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ribas A, Kim KB, Schuchter LM, et al, “BRIM-2: An Open-Label, Multicenter Phase II Study of Vemurafenib in Previously Treated Patients With BRAF V600E Mutation-Positive Metastatic Melanoma,” <i>J Clin Oncol</i>, 2011, 29(15s):8509 [abstract 8509 from ASCO 2011 Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23280631">
<a name="23280631"></a>Shah N, Iyer RM, Mair HJ, et al. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. <i>J Pharm Sci</i>. 2013;102(3):967-981.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/23280631/pubmed" id="23280631" target="_blank">23280631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22356324">
<a name="22356324"></a>Sosman JA, Kim KB, Schuchter L, et al, “Survival in BRAF V600-Mutant Advanced Melanoma Treated With Vemurafenib,” <i>N Engl J Med</i>, 2012, 366(8):707-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/22356324/pubmed" id="22356324" target="_blank">22356324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22256804">
<a name="22256804"></a>Su F, Viros A, Milagre C, et al, “RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated With BRAF Inhibitors,” <i>N Engl J Med</i>, 2012, 366(3):207-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/22256804/pubmed" id="22256804" target="_blank">22256804</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Su F, Yang H, Higgins B, et al, “Molecular Mechanisms Underlying Disease Relapse on Treatment With Selective BRAF Inhibitor Vemurafenib (PLX4032),” <i>J Clin Oncol</i>, 2011, 29(15s):8517 [abstract 8517 from ASCO 2011 Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30392755">
<a name="30392755"></a>Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. <i>J Am Acad Dermatol</i>. 2019;80(1):208-250. doi:10.1016/j.jaad.2018.08.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/30392755/pubmed" id="30392755" target="_blank">30392755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33979489">
<a name="33979489"></a>Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. <i>N Engl J Med</i>. 2021;384(19):1810-1823. doi:10.1056/NEJMoa2031298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/33979489/pubmed" id="33979489" target="_blank">33979489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26352686">
<a name="26352686"></a>Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. <i>N Engl J Med</i>. 2015;373(18):1733-1747. doi:10.1056/NEJMoa1506583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/26352686/pubmed" id="26352686" target="_blank">26352686</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26303964">
<a name="26303964"></a>Vandersleyen V, Grosber M, Wilgenhof S, et al. Vemurafenib-associated Dupuytren- and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients. <i>J Eur Acad Dermatol Venereol.</i> 2016;30(7):1133-1135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vemurafenib-drug-information/abstract-text/26303964/pubmed" id="26303964" target="_blank">26303964</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; May 2020.</div>
</li>
<li>
<div class="reference">
                  Zelboraf (vemurafenib) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche Limited; December 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 16798 Version 304.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
